From Guangzhou to Munich（18）

1月30日中午12点，仁医医疗四人团队前往哥廷根大学医疗中心精神病学及精神治疗科拜访该科主任Wiltfang教授。精神病学及精神治疗科独立办公，距离医疗中心总院区1.3公里，设有独立的实验楼层，方便该科进行科研活动。Wiltfang教授携科研负责人Dr. Esselmann亲自接待仁医医疗团队。据Wiltfang教授介绍，该科为全年龄段的病人提供所有精神病学诊疗服务，共有175张病床，其中110张住院病床，65张日间病床。2019年门诊病人约6800人，年均住院病人约2000人。除了诊疗服务外，科研是该科日常工作的重点，科研成果及产出在全院64个临床科室及研究所中名列前五。得益于哥廷根整座城市的科研氛围，该科与马克斯普朗克多学科神经科学研究所等多个分所、哥廷根大学医疗中心各学科、德国神经退行性疾病中心等科研机构合作进行相关转化研究。Wiltfang教授本人的研究重点在分子/生物精神病学和非侵入性脑刺激。该科还设有6个教授席位，分别是分子精神病学、神经退行性疾病表观遗传学、表观遗传学及基因学、分子神经生物学、转化神经蛋白质组学及法医精神病学。Wiltfang教授还分享，为支持环保理念及进一步加强医教研之间的联系与合作，哥廷根大学医疗中心将投入11亿欧元将总院区进行翻新和改造，使其更符合可持续发展理念。随后Wiltfang教授及Dr. Esselmann带我们参观了会议室、科室主要诊疗区域及各实验室。多年来Wiltfang教授及其团队一直致力于开发阿尔茨海默症生物标志物引导的早期诊断，其团队已开发了一个全新的诊断系统-A β-两步免疫分析法，只需要通过血液化验，可以在早期临床前阶段，甚至是病人出现临床症状15年之前，对初期的阿尔茨海默病性痴呆进行精确鉴别，这为在全球范围内制定最有效的预防性治疗策略创造了可能性。Wiltfang教授将携手仁医医疗及中国三甲医院，建立基于血液的高通量阿尔茨海默症早期诊断系统，对高危患者进行早期筛查，并以药物或生活方式改善进行早期干预以延缓疾病发展。

At noon on January 30th, Gloryren’s team of four went to the Department of Psychiatry and Psychotherapy at the University Medical Center Göttingen to visit Prof. Wiltfang, the Director of the department. The Department of Psychiatry and Psychotherapy functions alone in its own building, which is 1.3 kilometers from the Medical Center. It enjoys graceful surroundings, providing pleasant environment for both outpatient and inpatient. The department also has a whole floor for scientific research use exclusively. Prof. Wiltfang, together with the head of research, Dr. Esselmann welcomed our team from Gloryren. Prof. Wiltfang introduced that the Department of Psychiatry and Psychotherapy provides all psychiatric diagnostic and treatment services to patients of all ages. It holds 175 beds, including 110 inpatient beds and 65 beds for day clinic patients. In 2019, the department received about 6,800 clinic patients, with about 2000 inpatients annually. In addition to medical services, scientific research is the focus of the department’s daily work. Its scientific research results and output are among the top five of 64 clinics, departments, and pre-clinical research institutes. Benefiting from the scientific research atmosphere of the whole city of Göttingen, the department has cooperation for translational research with multiple scientific research institutions such as Max Planck Institute for Multidisciplinary Neuroscience and other branches, other specialties of the University Medical Center Göttingen, and German Center for Neurodegenerative Diseases Göttingen. The focus of the research of Prof. Wiltfang lies in molecular/biological psychiatry and non-invasive brain stimulation.The Department of Psychiatry and Psychotherapy also has six more professors, and they respectively focus on Molecular Psychiatry, Epigenetics of Neurodegenerative Diseases, Epigenetics and Genetics, Molecular Neurobiology, Translational Neuroproteomics, and Forensic Psychiatry & Psychotherapy. Prof. Wiltfang also told us that to support the environmental-friendly idea and to facilitate close connections and cooperation between healthcare, teaching, and research, the University Medical Center Göttingen will invest 1.1 billion euros for renovating and transforming its central hospital, making it more consistent with the concept of sustainable development. Later, Prof. Wiltfang and Dr. Esselmann showed us around the meeting room, the main diagnosis and treatment areas, and the laboratories. For many years, Prof. Wiltfang and his team have dedicated themselves to developing biomarker-guided early diagnostics of Alzheimer's dementia, and they’ve developed a brand new system, namely the Aβ-2step-Immunoassay, which can accurately identify early stage Alzheimer's disease dementia in preclinical stages, even 15 years before the patient develops clinical symptoms, using only blood tests. This is the dawn of developing the most efficient preventive strategies worldwide. In the coming future, Prof. Wiltfang will join hand in hand with Gloryren and Grade Three Class A hospitals in China to build a high-performance early diagnostics system for Alzheimer's dementia based on blood assays. This system will allow early screening of high-risk patients and early intervention with medications or lifestyle changes to slow disease progression.